Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

How To Navigate Europe's Future Multifaceted Patent System

This article was originally published in Scrip

Executive Summary

In his latest article on Europe's future Unified Patent Court and unitary patent system, Paul England explains the connections between proceedings in the UPC and the European Patent Office, and how companies can go about using the two procedures at the same time.

You may also be interested in...



What Law Applies In The Unified Patent Court?

When the pan-European Unified Patent Court comes fully into force, it will have divisions in a number of EU member states. But given its geographical scope, what is the law that will apply to disputes in the court? In the latest in his series of columns on the UPC, Paul England explains the law applicable to infringement, validity and "objects of property".

How To File Actions In The Unified Patent Court

As preparations continue for the establishment of Europe's Unified Patent Court system, Paul England examines the structure of the court and the various factors that will determine where infringement and revocation actions are to be lodged.

What relief will the UPC offer against an infringer?

In his latest column on the future Unified Patent Court, Paul England outlines the remedies that will be available to injured parties in the case of infringement, and argues that the court will be a powerful forum for the enforcement of patent rights in Europe.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

SC029830

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel